VIRX
Ensign Peak Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-61,601
| Closed | -$33.5K | – | 1723 |
|
|
2024
Q2 | $33.5K | Sell |
61,601
-1,805
| -3% | -$981 | ﹤0.01% | 1709 |
|
|
2024
Q1 | $64.7K | Hold |
63,406
| – | – | ﹤0.01% | 1721 |
|
|
2023
Q4 | $36.1K | Hold |
63,406
| – | – | ﹤0.01% | 1734 |
|
|
2023
Q3 | $65.9K | Hold |
63,406
| – | – | ﹤0.01% | 1746 |
|
|
2023
Q2 | $89.4K | Hold |
63,406
| – | – | ﹤0.01% | 1753 |
|
|
2023
Q1 | $101K | Hold |
63,406
| – | – | ﹤0.01% | 1755 |
|
|
2022
Q4 | $92.6K | Hold |
63,406
| – | – | ﹤0.01% | 1767 |
|
|
2022
Q3 | $271K | Hold |
63,406
| – | – | ﹤0.01% | 1754 |
|
|
2022
Q2 | $246K | Buy |
63,406
+2,891
| +5% | +$11.2K | ﹤0.01% | 1734 |
|
|
2022
Q1 | $288K | Hold |
60,515
| – | – | ﹤0.01% | 1769 |
|
|
2021
Q4 | $221K | Buy |
+60,515
| New | +$221K | ﹤0.01% | 1904 |
|